Back to School: How biopharma can reboot drug development. Access exclusive analysis here

VectivBio reunites ex-Therachon management, VCs for short bowel program

VectivBio launches with $35M, hopes to build pipeline beyond the asset it was created to house

Eight months after a venture syndicate gained an exit via the sale of dwarfism company Therachon to Pfizer, the same investors have reunited to supply a $35 million round for VectivBio, a new spinout created to house a short bowel syndrome program left behind in the acquisition.

VectivBio AG will reunite several members of Therachon’s management team, as well as a syndicate that includes

Read the full 631 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers